Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Shensong Yangxin (SSYX), a standardized Chinese preparation, is widely utilized in arrhythmia treatment. This research sought to assess the clinical advantages of SSYX for persistent atrial fibrillation (PsAF).
Methods: We searched seven databases and two registries to identify randomized controlled trials (RCTs) assessing SSYX as an adjunctive treatment for PsAF. We assessed methodological quality with the Cochrane Risk of Bias Tool 2.0, and conducted meta-analyses with RevMan 5.4.
Results: The meta-analysis incorporated ten RCTs enrolling 1,713 patients with PsAF. SSYX combined with conventional treatments (CTs) significantly lowered the recurrence of AF compared to CTs alone (risk ratio [] = 0.65, 95% conffdence interval [] 0.56 to 0.75, < 0.001). The results also showed that SSYX contributed to the reduction of left atrial diameter ( = -1.41, 95% -2.48 to -0.34, < 0.001) and P-wave dispersion ( = -10.37, 95% -17.23 to -3.5, = 0.003). Safety analysis revealed that the combination of SSYX and CTs decreased adverse reaction incidence ( = 0.54, 95% 0.32 to 0.90, = 0.02). The certainty of evidence was graded as moderate to low.
Conclusion: SSYX showed potential in preventing AF recurrence in PsAF patients. Nevertheless, these preliminary findings require validation through more rigorously designed trials, given methodological limitations impacting evidence certainty.
Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251008974, identifier CRD420251008974.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12213544 | PMC |
| http://dx.doi.org/10.3389/fphar.2025.1620340 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of shensong yangxin capsules for persistent atrial fibrillation: a Systematic Review and meta-analysis of randomized controlled trials.
Front Pharmacol
June 2025
Department of Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Background: Shensong Yangxin (SSYX), a standardized Chinese preparation, is widely utilized in arrhythmia treatment. This research sought to assess the clinical advantages of SSYX for persistent atrial fibrillation (PsAF).
Methods: We searched seven databases and two registries to identify randomized controlled trials (RCTs) assessing SSYX as an adjunctive treatment for PsAF.
Insights into Q-marker of Shensong Yangxin capsule in treating cardiac arrhythmias based on a linear substitution strategy in quantification of multiple components.
Phytomedicine
March 2025
Institute of Traditional Chinese Medicine and Natural Products, College of Pharmacy, and International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), Jinan University, Guangzhou 510632, China. Electronic ad
Background: The concept of a Quality marker (Q-marker) has emerged as a crucial tool for ensuring the safety and efficacy of Traditional Chinese Medicine (TCM) formulas. However, significant challenges remained in the identification and practical application of Q-marker, particularly due to the scarcity of reference standards.
Purpose: This study aimed to achieve a multidimensional integration of chemical profiling, target tissue distribution and in vivo high-throughput screening model to effectively identify the Q-marker of Shensong Yangxin Capsule (SSYX) and propose a linear substitution strategy for the quantification of multiple components.
Shensong yangxin, a multi-functional traditional Chinese medicine for arrhythmia: A review of components, pharmacological mechanisms, and clinical applications.
Heliyon
August 2024
State Key Laboratory for Innovation and Transformation of Luobing Theory, Shijiazhuang, 050035, China.
As a common cardiovascular disease (CVD), Arrhythmia refers to any abnormality in the origin, frequency, rhythm, conduction velocity, timing, pathway, sequence, or other aspect of cardiac impulses, and it is one of the common cardiovascular diseases in clinical practice. At present, various ion channel blockers are used for treatment of arrhythmia that include Na ion channel blockers, K ion channel blockers and Ca ion channel blockers. While these drugs offer benefits, they have led to a gradual increase in drug-related adverse reactions across various systems.
View Article and Find Full Text PDFAtrial tachyarrhythmia prevention by Shensong Yangxin after catheter ablation for persistent atrial fibrillation: the SS-AFRF trial.
Eur Heart J
October 2024
Department of Cardiology, Hebei Yiling Hospital, 385 Xinshibei Road, Shijiazhuang 050091, China.
Background And Aims: Despite advances in technology and techniques, the recurrence rate of persistent atrial fibrillation (AF) following catheter ablation remains high. The Shensong Yangxin (SSYX) capsule, a renowned traditional Chinese medicine formula, is used in the treatment of cardiac arrhythmias. This trial aimed to investigate whether the SSYX can improve clinical outcomes in patients who have undergone catheter ablation for persistent AF.
View Article and Find Full Text PDFEfficacy of Shensong Yangxin capsule combined with dronedarone in paroxysmal atrial fibrillation after ablation.
Medicine (Baltimore)
April 2024
Sichuan Mianyang 404 Hospital, Mianyang, China.
Objective: To investigate whether postoperative administration of Shensong Yangxin capsules (SSYX) and dronedarone for atrial fibrillation (AF) can reduce the recurrence of paroxysmal AF after radiofrequency ablation, thus providing a more optimal choice of antiarrhythmic medication during the blank period.
Methods: We included 120 patients with paroxysmal AF who underwent radiofrequency ablation at our hospital between July 2020 and July 2022. They underwent routine circumferential pulmonary vein ablation and, subsequently, left and right atrial pressure monitoring to assess sinoatrial node recovery time under burst 400/300 ms stimulation.